113 related articles for article (PubMed ID: 20012574)
21. CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.
Kohlmeyer JL; Gordon DJ; Tanas MR; Monga V; Dodd RD; Quelle DE
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344731
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment.
Sharma PS; Sharma R; Tyagi R
Curr Cancer Drug Targets; 2008 Feb; 8(1):53-75. PubMed ID: 18288944
[TBL] [Abstract][Full Text] [Related]
23. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
24. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Jorda R; Hendrychová D; Voller J; Řezníčková E; Gucký T; Kryštof V
J Med Chem; 2018 Oct; 61(20):9105-9120. PubMed ID: 30234987
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.
Johnson N; Shapiro GI
Expert Opin Ther Targets; 2010 Nov; 14(11):1199-212. PubMed ID: 20932174
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.
Liu Y; Fu L; Wu J; Liu M; Wang G; Liu B; Zhang L
Eur J Med Chem; 2022 Feb; 229():114056. PubMed ID: 34942431
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Basso AD; Doll RJ
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
[TBL] [Abstract][Full Text] [Related]
28. Metabolomic Applications to the Characterization of the Mode-of-Action of CDK Inhibitors.
Palomino-Schätzlein M; Pineda-Lucena A
Methods Mol Biol; 2016; 1336():211-23. PubMed ID: 26231718
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
Stone A; Sutherland RL; Musgrove EA
Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
[TBL] [Abstract][Full Text] [Related]
30. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
[TBL] [Abstract][Full Text] [Related]
31. CDK inhibition and cancer therapy.
Garrett MD; Fattaey A
Curr Opin Genet Dev; 1999 Feb; 9(1):104-11. PubMed ID: 10072351
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications.
Sofi S; Mehraj U; Qayoom H; Aisha S; Asdaq SMB; Almilaibary A; Mir MA
Med Oncol; 2022 Apr; 39(6):106. PubMed ID: 35486263
[TBL] [Abstract][Full Text] [Related]
33. A Photoaffinity Displacement Assay and Probes to Study the Cyclin-Dependent Kinase Family.
Grant EK; Fallon DJ; Eberl HC; Fantom KGM; Zappacosta F; Messenger C; Tomkinson NCO; Bush JT
Angew Chem Int Ed Engl; 2019 Nov; 58(48):17322-17327. PubMed ID: 31518032
[TBL] [Abstract][Full Text] [Related]
34. Understanding the Structural Basis for Inhibition of Cyclin-Dependent Kinases. New Pieces in the Molecular Puzzle.
Levin NMB; Pintro VO; de Avila MB; de Mattos BB; De Azevedo WF
Curr Drug Targets; 2017; 18(9):1104-1111. PubMed ID: 27848884
[TBL] [Abstract][Full Text] [Related]
35. Clinical anticancer drug development: targeting the cyclin-dependent kinases.
Benson C; Kaye S; Workman P; Garrett M; Walton M; de Bono J
Br J Cancer; 2005 Jan; 92(1):7-12. PubMed ID: 15558073
[TBL] [Abstract][Full Text] [Related]
36. Mammalian interphase cdks: dispensable master regulators of the cell cycle.
Enders GH
Genes Cancer; 2012 Nov; 3(11-12):614-8. PubMed ID: 23634250
[TBL] [Abstract][Full Text] [Related]
37. Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes.
Kashanchi F; Kehn-Hall K
Curr Pharm Des; 2009; 15(21):2520-32. PubMed ID: 19601848
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
Marak BN; Dowarah J; Khiangte L; Singh VP
Eur J Med Chem; 2020 Oct; 203():112571. PubMed ID: 32707525
[TBL] [Abstract][Full Text] [Related]
39. Opinion Paper: Targeting Multiple Cyclin-Dependent Kinases (CDKs): A New Strategy for Molecular Docking Studies.
de Azevedo WF
Curr Drug Targets; 2016; 17(1):2. PubMed ID: 26687602
[No Abstract] [Full Text] [Related]
40. The cardiac cell cycle, pocket proteins, and p300.
Kirshenbaum LA; Schneider MD
Trends Cardiovasc Med; 1995; 5(6):230-5. PubMed ID: 21232265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
